{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:39:54Z","timestamp":1794137994781,"version":"4.8.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Stempeutics Research Pvt Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We have previously demonstrated that a pooled population of bone marrow-derived, allogeneic mesenchymal stromal cells (BMMSC), Stempeucel\u00ae-1, produced under good manufacturing practices (GMP) conditions, showed clinical efficacy and safety in patients suffering from critical limb ischemia (CLI) due to Buerger\u2019s disease. While Stempeucel\u00ae-1 is currently used for CLI and other clinical indications, we wanted to ensure that the product\u2019s continuity is addressed by developing and characterizing a second generation of pooled product (Stempeucel\u00ae-1A), manufactured identically from second BM aspirates of the same three donors after a 2-year interval.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The two versions of Stempeucel\u00ae were manufactured and subjected to gene and protein expression analysis. The nature of various growth factors\/cytokines secreted and immunomodulatory activity of these two cell populations were compared directly by various in vitro assays. The preclinical efficacy of these two cell types was compared in an experimental model of hind limb ischemia (HLI) in BALB\/c nude mice. The reversal of ischemia, blood flow, and muscle regeneration were determined by functional scoring, laser Doppler imaging, and immunohistochemical analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Qualitative and quantitative analyses of genes and proteins involved in promoting angiogenic activity and immune regulatory functions revealed high levels of correlation between Stempeucel\u00ae-1 and Stempeucel\u00ae-1A cell populations. Moreover, intramuscular (i.m) administration of these two cell products in the ischemic limbs of BALB\/c nude mice showed significant repair (\u2265\u200970%) of toe and foot necrosis, leading to improved ambulatory function and limb salvage. Furthermore, a biodistribution kinetics study showed that Stempeucel\u00ae-1 was mostly localized in the ischemic muscles of mice for a significantly longer time compared to normal muscles, thus playing an essential role in modulating and reversing HLI damage.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study shows that with a reproducible manufacturing procedure, it is possible to generate large numbers of pooled mesenchymal stromal cells from human bone marrow samples to establish product equivalence. We conclude from these results that, for the first time, two pooled, allogeneic BMMSC products can be repeatedly manufactured at different time intervals using a two-tier cell banking process with robust and comparable angiogenic properties to treat ischemic diseases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13287-021-02330-9","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T08:03:56Z","timestamp":1620633836000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Human bone marrow-derived, pooled, allogeneic mesenchymal stromal cells manufactured from multiple donors at different times show comparable biological functions in vitro, and in vivo to repair limb ischemia"],"prefix":"10.1186","volume":"12","author":[{"given":"Charan","family":"Thej","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathiyazhagan","family":"Rengasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Walvekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Swamynathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi Sundar","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradnya","family":"Shahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Siddikuzzaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udaykumar","family":"Kolkundkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raviraja N.","family":"Seetharam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawan Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish S.","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"issue":"4","key":"2330_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/sctm.19-0319","volume":"9","author":"R Gianni-Barrera","year":"2020","unstructured":"Gianni-Barrera R, Di Maggio N, Melly L, Burger MG, Mujagic E, G\u00fcrke L, et al. Therapeutic vascularization in regenerative medicine. Stem Cells Transl Med. 2020;9(4):433\u201344. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/sctm.19-0319.","journal-title":"Stem Cells Transl Med"},{"key":"2330_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1358863X17752556","volume":"23","author":"T Pan","year":"2018","unstructured":"Pan T, Wei Z, Fang Y, Dong Z, Fu W. Therapeutic efficacy of CD34 + cell-involved mononuclear cell therapy for no-option critical limb ischemia: a meta-analysis of randomized controlled clinical trials. Vasc Med. 2018;23:219\u201331. Available from: http:\/\/journals.sagepub.com\/doi\/10.1177\/1358863X17752556","journal-title":"Vasc Med"},{"key":"2330_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/4137626","volume":"2017","author":"V Ponemone","year":"2017","unstructured":"Ponemone V, Gupta S, Sethi D, Suthar M, Sharma M, Powell RJ, Harris KL, Jungla N, Arambam P, Kaul U, Seth A, Bukhari S. Safety and effectiveness of bone marrow cell concentrate in the treatment of chronic critical limb ischemia utilizing a rapid point-of-care system. Stem Cells Int. 2017;2017:1\u201316. Available from: https:\/\/www.hindawi.com\/journals\/sci\/2017\/4137626\/. https:\/\/doi.org\/10.1155\/2017\/4137626.","journal-title":"Stem Cells Int"},{"key":"2330_CR4","doi-asserted-by":"crossref","unstructured":"Keighron C, Lyons CJ, Creane M, O'Brien T, Liew A. Recent advances in endothelial progenitor cells toward their use in clinical translation. Front Med. 2018;5 Available from:\u00a0https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2018.00354\/full. Accessed 3 May 2020.","DOI":"10.3389\/fmed.2018.00354"},{"key":"2330_CR5","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1161\/CIRCULATIONAHA.112.116103","volume":"127","author":"JC Ryu","year":"2013","unstructured":"Ryu JC, Davidson BP, Xie A, Qi Y, Zha D, Belcik JT, et al. Molecular imaging of the paracrine proangiogenic effects of progenitor cell therapy in limb ischemia. Circulation. 2013;127:710\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23307829","journal-title":"Circulation"},{"key":"2330_CR6","unstructured":"Raval Z, Losordo D. Cell therapy of peripheral arterial disease from experimental findings to clinical trials. Circ Res. 2013;112 Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCRESAHA.113.300565?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.\u00a0Accessed 1 Feb 2019."},{"key":"2330_CR7","doi-asserted-by":"crossref","unstructured":"Das AK, Gupta PK, Anoop CH, Balasubramanian S, Majumdar AS. Mesenchymal stem cell therapy for peripheral vascular diseases. Mesenchymal Stem Cell Ther. 2013;405\u201321. Available from:\u00a0http:\/\/link.springer.com\/10.1007\/978-1-62703-200-1_18. Accessed 1 Feb 2019.","DOI":"10.1007\/978-1-62703-200-1_18"},{"key":"2330_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12967-019-1877-4","volume":"17","author":"A Trivedi","year":"2019","unstructured":"Trivedi A, Miyazawa B, Gibb S, Valanoski K, Vivona L, Lin M, et al. Bone marrow donor selection and characterization of MSCs is critical for pre-clinical and clinical cell dose production. J Transl Med. 2019;17:128. Available from: https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-019-1877-4","journal-title":"J Transl Med"},{"key":"2330_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/scrt119","volume":"3","author":"A Liew","year":"2012","unstructured":"Liew A, O'Brien T. Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia. Stem Cell Res Ther. 2012;3:28. Available from: http:\/\/tc.liblink.umn.edu\/sfx_local?sid=OVID:medline&id=pmid:22846185&id=doi:10.1186%2Fscrt119&issn=1757-6512&isbn=&volume=3&issue=4&spage=28&pages=28&date=2012&title=Stem+Cell+Research+%26+Therapy&atitle=Therapeutic+potential+for+mesenchymal+stem+cell+tr","journal-title":"Stem Cell Res Ther"},{"key":"2330_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315\u20137. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1465324906708817","journal-title":"Cytotherapy"},{"key":"2330_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4103\/2229-3485.83228","volume":"2","author":"B George","year":"2011","unstructured":"George B. Regulations and guidelines governing stem cell based products: clinical considerations. Perspect Clin Res. 2011;2:94\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21897884","journal-title":"Perspect Clin Res"},{"key":"2330_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/1479-5876-11-143","volume":"11","author":"PK Gupta","year":"2013","unstructured":"Gupta PK, Chullikana A, Parakh R, Desai S, Das A, Gottipamula S, et al. A double blind randomized placebo controlled phase I\/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. J Transl Med. 2013;11:143. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3688296&tool=pmcentrez&rendertype=abstract","journal-title":"J Transl Med"},{"issue":"3","key":"2330_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.5966\/sctm.2016-0237","volume":"6","author":"PK Gupta","year":"2017","unstructured":"Gupta PK, Krishna M, Chullikana A, Desai S, Murugesan R, Dutta S, et al. Administration of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells in critical limb ischemia due to Buerger\u2019s disease: phase II study report suggests clinical efficacy. Stem Cells Transl Med. 2017;6(3):689\u201399. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27708131","journal-title":"Stem Cells Transl Med"},{"issue":"10","key":"2330_CR14","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1002\/jcb.24193","volume":"113","author":"MK Mamidi","year":"2012","unstructured":"Mamidi MK, Nathan KG, Singh G, Thrichelvam ST, Mohd Yusof NAN, Fakharuzi NA, Zakaria Z, Bhonde R, Das AK, Majumdar AS. Comparative cellular and molecular analyses of pooled bone marrow multipotent mesenchymal stromal cells during continuous passaging and after successive cryopreservation. J Cell Biochem. 2012;113(10):3153\u201364. https:\/\/doi.org\/10.1002\/jcb.24193.","journal-title":"J Cell Biochem"},{"key":"2330_CR15","doi-asserted-by":"publisher","unstructured":"Chullikana A, Majumdar A Sen, Gottipamula S, Krishnamurthy S, Kumar AS, Prakash VS, et al. Randomized, double-blind, phase I\/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. Cytotherapy. 2015;17(3):250-61. https:\/\/doi.org\/10.1016\/j.jcyt.2014.10.009. Epub 2014 Dec 4.","DOI":"10.1016\/j.jcyt.2014.10.009"},{"key":"2330_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00441-013-1783-7","volume":"356","author":"S Gottipamula","year":"2014","unstructured":"Gottipamula S, Ashwin KM, Muttigi MS, Kannan S, Kolkundkar U, Seetharam RN. Isolation, expansion and characterization of bone marrow-derived mesenchymal stromal cells in serum-free conditions. Cell Tissue Res. 2014;356:123\u201335. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24448665","journal-title":"Cell Tissue Res"},{"key":"2330_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13287-017-0488-3","volume":"8","author":"C Thej","year":"2017","unstructured":"Thej C, Ramadasse B, Walvekar A, Majumdar AS, Balasubramanian S, et al. Stem Cell Res Ther. 2017;8:47. Available from: http:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-017-0488-3","journal-title":"Stem Cell Res Ther"},{"key":"2330_CR18","doi-asserted-by":"crossref","unstructured":"Goto T, Fukuyama N, Aki A, Kanabuchi K, Kimura K, Taira H, Tanaka E, Wakana N, Mori H, Inoue H. Search for appropriate experimental methods to create stable hind-limb ischemia in mouse. Tokai J Exp Clin Med. 2006;31(3):128\u201332.","DOI":"10.1111\/j.1365-2230.2005.02036.x"},{"key":"2330_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5051\/jpis.2011.41.4.192","volume":"41","author":"S-H Kim","year":"2011","unstructured":"Kim S-H, Kim Y-S, Lee S-Y, Kim K-H, Lee Y-M, Kim W-K, et al. Gene expression profile in mesenchymal stem cells derived from dental tissues and bone marrow. J Periodontal Implant Sci. 2011;41:192\u2013200. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21954424","journal-title":"J Periodontal Implant Sci"},{"key":"2330_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/term.1713","volume":"10","author":"S Gottipamula","year":"2016","unstructured":"Gottipamula S, Muttigi MS, Chaansa S, Ashwin KM, Priya N, Kolkundkar U, et al. Large-scale expansion of pre-isolated bone marrow mesenchymal stromal cells in serum-free conditions. J Tissue Eng Regen Med. 2016;10:108\u201319. Available from: http:\/\/doi.wiley.com\/10.1002\/term.1713","journal-title":"J Tissue Eng Regen Med"},{"issue":"6","key":"2330_CR21","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/j.jvs.2012.04.067","volume":"56","author":"RA Brenes","year":"2012","unstructured":"Brenes RA, Jadlowiec CC, Bear M, Hashim P, Protack CD, Li X, Lv W, Collins MJ, Dardik A. Toward a mouse model of hind limb ischemia to test therapeutic angiogenesis. J Vasc Surg. 2012;56(6):1669\u201379. https:\/\/doi.org\/10.1016\/j.jvs.2012.04.067.","journal-title":"J Vasc Surg"},{"key":"2330_CR22","doi-asserted-by":"publisher","first-page":"852","DOI":"10.4103\/ijmr.IJMR_1842_15","volume":"144","author":"M Rengasamy","year":"2016","unstructured":"Rengasamy M, Gupta PK, Kolkundkar U, Singh G, Balasubramanian S, SundarRaj S, et al. Preclinical safety & toxicity evaluation of pooled, allogeneic human bone marrow-derived mesenchymal stromal cells. Indian J Med Res. 2016;144:852\u201364. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28474622","journal-title":"Indian J Med Res"},{"key":"2330_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13287-017-0595-1","volume":"8","author":"M Rengasamy","year":"2017","unstructured":"Rengasamy M, Singh G, Fakharuzi NA, Siddikuzzaman BS, Swamynathan P, et al. Transplantation of human bone marrow mesenchymal stromal cells reduces liver fibrosis more effectively than Wharton\u2019s jelly mesenchymal stromal cells. Stem Cell Res Ther. 2017;8:143. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28610623","journal-title":"Stem Cell Res Ther"},{"key":"2330_CR24","doi-asserted-by":"crossref","unstructured":"Noronha NC N de C, Mizukami A, Cali\u00e1ri-Oliveira C, Cominal JG, Rocha JLM, Covas DT, et al. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res Ther. 2019;10:131. Available from: https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-019-1224-y","DOI":"10.1186\/s13287-019-1224-y"},{"key":"2330_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1161\/01.RES.0000124603.46777.EB","volume":"94","author":"M Heil","year":"2004","unstructured":"Heil M, Ziegelhoeffer T, Mees B, Schaper W. A different outlook on the role of bone marrow stem cells in vascular growth: bone marrow delivers software not hardware. Circ Res. 2004;94:573\u20134. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15031269","journal-title":"Circ Res"},{"key":"2330_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0140-6736(02)09670-8","volume":"360","author":"E Tateishi-Yuyama","year":"2002","unstructured":"Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360:427\u201335. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12241713","journal-title":"Lancet"},{"key":"2330_CR27","doi-asserted-by":"crossref","unstructured":"Campbell A, Brieva T, Raviv L, Rowley J, Niss K, Brandwein H, Oh S, Karnieli O. Concise review: process development considerations for cell therapy. Stem Cells Transl Med. 2015;4(10):1155\u201363. Available from: http:\/\/doi.wiley.com\/10.5966\/sctm.2014-0294.\u00a0Accessed 15 July 2020.","DOI":"10.5966\/sctm.2014-0294"},{"key":"2330_CR28","doi-asserted-by":"crossref","unstructured":"Lehman N, Cutrone R, Raber A, Perry R, Van'T Hof W, Deans R, et al. Development of a surrogate angiogenic potency assay for clinical-grade stem cell production. Cytotherapy. 2012","DOI":"10.3109\/14653249.2012.688945"},{"key":"2330_CR29","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.4049\/jimmunol.1301828","volume":"192","author":"R Chinnadurai","year":"2014","unstructured":"Chinnadurai R, Copland IB, Patel SR, Galipeau J. IDO-independent suppression of T cell effector function by IFN- -licensed human mesenchymal stromal cells. J Immunol. 2014;192:1491\u2013501. Available from: http:\/\/www.jimmunol.org\/cgi\/doi\/10.4049\/jimmunol.1301828","journal-title":"J Immunol"},{"key":"2330_CR30","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1002\/stem.2415","volume":"34","author":"R Chinnadurai","year":"2016","unstructured":"Chinnadurai R, Copland IB, Garcia MA, Petersen CT, Lewis CN, Waller EK, et al. Cryopreserved mesenchymal stromal cells are susceptible to T-cell mediated apoptosis which is partly rescued by IFN\u03b3 licensing. Stem Cells. 2016;34:2429\u201342. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27299362","journal-title":"Stem Cells"},{"key":"2330_CR31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ebiom.2018.01.002","volume":"28","author":"DS Kim","year":"2018","unstructured":"Kim DS, Jang IK, Lee MW, Ko YJ, Lee D-H, Lee JW, et al. Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-\u03b3. EBioMedicine. 2018;28:261\u201373. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29366627","journal-title":"EBioMedicine"},{"issue":"4","key":"2330_CR32","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ejvs.2018.11.008","volume":"57","author":"L Norgren","year":"2019","unstructured":"Norgren L, Weiss N, Nikol S, Hinchliffe RJ, Lantis JC, Patel MR, Reinecke H, Ofir R, Rosen Y, Peres D, Aberman Z. PLX-PAD cell treatment of critical limb ischaemia: rationale and design of the PACE trial. Eur J Vasc Endovasc Surg. 2019;57(4):538\u201345. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078588418308566. https:\/\/doi.org\/10.1016\/j.ejvs.2018.11.008.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2330_CR33","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1161\/ATVBAHA.113.302592","volume":"34","author":"R Katare","year":"2014","unstructured":"Katare R, Stroemer P, Hicks C, Stevanato L, Patel S, Corteling R, et al. Clinical-grade human neural stem cells promote reparative neovascularization in mouse models of hindlimb ischemia. Arterioscler Thromb Vasc Biol. 2014;34:408\u201318. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24202301","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02330-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-021-02330-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02330-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T08:12:12Z","timestamp":1620634332000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-021-02330-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2330"],"URL":"https:\/\/doi.org\/10.1186\/s13287-021-02330-9","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]},"assertion":[{"value":"8 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bone marrow aspiration from consenting healthy donors was approved by the Institutional Ethics Committee (IEC) of Kasturba Hospital, Manipal, Karnataka. The reference number for approval is SRPL\/CLI\/07-08\/001.The animal experimental protocol was approved by the Institutional Animal Ethics Committee (IAEC) (Syngene\/IAEC\/388\/05-2013) of Syngene International animal facility. Animals were maintained at the same facility and all the animal experiments were conducted in the same facility in accordance with the experimental ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"279"}}